Robecosam AG reduced its stake in Danaher Co. (NYSE:DHR) by 7.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 503,699 shares of the conglomerate’s stock after selling 40,648 shares during the quarter. Danaher comprises 3.1% of Robecosam AG’s holdings, making the stock its 3rd largest holding. Robecosam AG owned about 0.07% of Danaher worth $47,126,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors also recently bought and sold shares of DHR. Xact Kapitalforvaltning AB lifted its stake in shares of Danaher by 1.4% in the third quarter. Xact Kapitalforvaltning AB now owns 102,965 shares of the conglomerate’s stock worth $8,832,000 after acquiring an additional 1,415 shares during the period. Stock Yards Bank & Trust Co. increased its holdings in Danaher by 1.2% in the third quarter. Stock Yards Bank & Trust Co. now owns 159,978 shares of the conglomerate’s stock worth $13,723,000 after purchasing an additional 1,849 shares in the last quarter. Tirschwell & Loewy Inc. increased its holdings in Danaher by 0.6% in the third quarter. Tirschwell & Loewy Inc. now owns 243,960 shares of the conglomerate’s stock worth $20,927,000 after purchasing an additional 1,525 shares in the last quarter. Intermede Investment Partners Ltd increased its holdings in Danaher by 1.5% in the third quarter. Intermede Investment Partners Ltd now owns 443,856 shares of the conglomerate’s stock worth $38,074,000 after purchasing an additional 6,422 shares in the last quarter. Finally, Davis R M Inc. increased its holdings in Danaher by 0.9% in the third quarter. Davis R M Inc. now owns 406,211 shares of the conglomerate’s stock worth $34,845,000 after purchasing an additional 3,592 shares in the last quarter. 77.83% of the stock is currently owned by institutional investors.
Shares of Danaher Co. (DHR) opened at $103.74 on Monday. Danaher Co. has a 1-year low of $78.97 and a 1-year high of $104.82. The stock has a market capitalization of $72,365.85, a price-to-earnings ratio of 29.39, a P/E/G ratio of 2.18 and a beta of 1.03. The company has a current ratio of 1.43, a quick ratio of 1.05 and a debt-to-equity ratio of 0.39.
The business also recently declared a quarterly dividend, which will be paid on Friday, April 27th. Investors of record on Thursday, March 29th will be issued a dividend of $0.16 per share. The ex-dividend date is Wednesday, March 28th. This represents a $0.64 annualized dividend and a yield of 0.62%. This is an increase from Danaher’s previous quarterly dividend of $0.14. Danaher’s dividend payout ratio is 15.86%.
In other Danaher news, SVP Angela S. Lalor sold 42,988 shares of the business’s stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $102.29, for a total value of $4,397,242.52. Following the transaction, the senior vice president now owns 82,008 shares of the company’s stock, valued at $8,388,598.32. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Daniel L. Comas sold 62,989 shares of the business’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $101.96, for a total value of $6,422,358.44. Following the completion of the transaction, the chief financial officer now directly owns 227,805 shares in the company, valued at approximately $23,226,997.80. The disclosure for this sale can be found here. Insiders have sold 313,260 shares of company stock valued at $31,657,786 in the last quarter. 12.20% of the stock is currently owned by corporate insiders.
A number of brokerages have weighed in on DHR. Credit Suisse Group lifted their target price on Danaher from $99.00 to $105.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. Stifel Nicolaus lifted their target price on Danaher from $110.00 to $115.00 and gave the stock a “buy” rating in a report on Wednesday, January 31st. Zacks Investment Research downgraded Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, December 19th. Robert W. Baird reiterated a “buy” rating on shares of Danaher in a report on Friday, January 12th. Finally, UBS Group began coverage on Danaher in a report on Monday, January 22nd. They issued a “buy” rating and a $99.97 target price for the company. One research analyst has rated the stock with a sell rating, six have given a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $101.23.
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.